| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis J Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ... Blood 109 (8), 3207-3213, 2007 | 574 | 2007 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ... Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 2007 | 542 | 2007 |
| Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two‐year follow‐up of a randomized … H Kantarjian, R Pasquini, V Lévy, S Jootar, J Holowiecki, N Hamerschlak, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 300 | 2009 |
| Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis PA Muraro, M Pasquini, HL Atkins, JD Bowen, D Farge, A Fassas, ... JAMA neurology 74 (4), 459-469, 2017 | 286 | 2017 |
| Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase J Cortes, DW Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, ... Leukemia 22 (12), 2176-2183, 2008 | 258 | 2008 |
| BCL-2 as therapeutic target for hematological malignancies GF Perini, GN Ribeiro, JV Pinto Neto, LT Campos, N Hamerschlak Journal of hematology & oncology 11, 1-15, 2018 | 214 | 2018 |
| Improvement in the outcome of invasive fusariosis in the last decade M Nucci, KA Marr, M Vehreschild, C De Souza, E Velasco, P Cappellano, ... Clinical Microbiology and Infection 20 (6), 580-585, 2014 | 198 | 2014 |
| Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study I Esteves, C Bonfim, R Pasquini, V Funke, NF Pereira, V Rocha, Y Novis, ... Bone marrow transplantation 50 (5), 685-689, 2015 | 175 | 2015 |
| História da hemoterapia no Brasil PC Junqueira, J Rosenblit, N Hamerschlak Revista Brasileira de Hematologia e Hemoterapia 27, 201-207, 2005 | 151 | 2005 |
| Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma OA O’Connor, M Özcan, ED Jacobsen, JM Roncero, J Trotman, J Demeter, ... Journal of Clinical Oncology 37 (8), 613-623, 2019 | 127 | 2019 |
| Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation GM Dotoli, GC De Santis, MD Orellana, K de Lima Prata, SR Caruso, ... Bone marrow transplantation 52 (6), 859-862, 2017 | 120 | 2017 |
| Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease DC Fajgenbaum, RA Langan, AS Japp, HL Partridge, SK Pierson, ... The Journal of clinical investigation 129 (10), 4451-4463, 2019 | 119 | 2019 |
| Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG N Hamerschlak, M Rodrigues, DA Moraes, MC Oliveira, ABPL Stracieri, ... Bone Marrow Transplantation 45 (2), 239-248, 2010 | 116 | 2010 |
| Myeloablative reduced-toxicity iv busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in … G Alatrash, M De Lima, N Hamerschlak, M Pelosini, X Wang, L Xiao, ... Biology of Blood and Marrow Transplantation 17 (10), 1490-1496, 2011 | 106 | 2011 |
| Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study E Maluf, N Hamerschlak, AB Cavalcanti, ÁA Júnior, J Eluf-Neto, ... Haematologica 94 (9), 1220, 2009 | 104 | 2009 |
| Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial F de Paula Eduardo, L Corrêa, D Heller, CA Daep, C Benitez, Z Malheiros, ... Heliyon 7 (6), 2021 | 103 | 2021 |
| Cost‐effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation LM Bezinelli, F de Paula Eduardo, RM da Graça Lopes, MGH Biazevic, ... Hematological oncology 32 (1), 31-39, 2014 | 98 | 2014 |
| Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study ME Horwitz, PJ Stiff, C Cutler, C Brunstein, R Hanna, RT Maziarz, ... Blood, The Journal of the American Society of Hematology 138 (16), 1429-1440, 2021 | 90 | 2021 |
| Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research MC Pasquini, J Voltarelli, HL Atkins, N Hamerschlak, X Zhong, KW Ahn, ... Biology of Blood and Marrow Transplantation 18 (10), 1471-1478, 2012 | 85 | 2012 |
| Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004) M Scheinberg, N Hamerschlak, JM Kutner, AAF Ribeiro, E Ferreira, ... Clinical and experimental rheumatology 24 (1), 65, 2006 | 84 | 2006 |
